In a bid to bolster its immunology and neurology pipeline, Takeda has entered into a collaboration agreement with BridGene Biosciences to discover small molecules for immunology and neurology targets. The deal, which is worth up to US$816 M, provides Takeda with access to BridGene’s chemoproteomic platform, IMTAC, to develop and advance small molecule drugs to address unmet medical needs. The deal marks yet another partnership for BridGene driven by its IMTAC platform, following its alliance with Galapagos on small molecule therapeutics in January 2024.